Santos Imini (STOJOF) News

CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population

Multikine significantly increases overall survival in patients with low levels of tumor cell PD-L1 expression...

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

Dr. Selvaggi was instrumental in the development and approval of lung cancer drugs Zykadia for Novartis and...

CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended March 31, 2024, as well as key recent clinical...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer

Critical milestone achieved—the FDA accepted CEL-SCI’s selection criteria defining the Multikine target population before surgery Selected...

CEL-SCI Appoints Mario Gobbo to Its Board of Directors

CEL-SCI Corporation (NYSE American: CVM) today announced the appointment of Mario Gobbo to its Board of Directors. Mr. Gobbo has nearly 40 years...

CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology

CEL-4000 may deliver safe and effective therapy for RA by rebalancing the inflammatory response, without weakening important immune defense...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements

CEL-SCI Corporation Issues Letter to Shareholders

CEL-SCI Corporation (NYSE American: CVM) today issued a letter to its shareholders. This letter will be sent to the Company’s shareholders along...